Seroatlas · Human Serome Atlas

BCL9L

B-cell CLL/lymphoma 9-like protein

Also known as: B9L, Bcl9-2, BCL9L_HUMAN, DLNB11

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86UU0
Gene: BCL9L
Ensembl: ENSG00000186174
Chromosome: 11
Canonical length: 1499 aa
Protein class: Cancer-related genes, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nucleoli fibrillar center

OverviewNCBI Gene

Enables beta-catenin binding activity. Involved in several processes, including negative regulation of transforming growth factor beta receptor signaling pathway; positive regulation of epithelial to mesenchymal transition; and positive regulation of transcription by RNA polymerase II. Located in fibrillar center and nucleoplasm. Part of beta-catenin-TCF complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

1499 residues, UniProt reviewed canonical sequence.

>Q86UU0|BCL9L
     1  MRILANKTRL PHPRRREAPG SPPLSPRGHC PPAPAKPMHP ENKLTNHGKT GNGGAQSQHQ
    61  NVNQGPTCNV GSKGVGAGNH GAKANQISPS NSSLKNPQAG VPPFSSLKGK VKRDRSVSVD
   121  SGEQREAGTP SLDSEAKEVA PRSKRRCVLE RKQPYSGDEW CSGPDSEEDD KPIGATHNCN
   181  VADPAMAAPQ LGPGQTTQLP LSESSVPGAP HGPPPGLRPD APGGGGGGGG VPGKPPSQFV
   241  YVFTTHLANT AAEAVLQGRA DSILAYHQQN VPRAKLDQAP KVPPTPEPLP LSTPSAGTPQ
   301  SQPPPLPPPP PPAPGSAPPA LPPEGPPEDS SQDLAPNSVG AASTGGGTGG THPNTPTATT
   361  ANNPLPPGGD PSSAPGPALL GEAAAPGNGQ RSLVGSEGLS KEQLEHRERS LQTLRDIERL
   421  LLRSGETEPF LKGPPGGAGE GGPPAQAPPP PQQPPTAPPS GLKKYEEPLQ SMISQTQSLG
   481  GPPLEHEVPG HPPGGDMGQQ MNMMIQRLGQ DSLTPEQVAW RKLQEEYYEE KRRKEEQIGL
   541  HGSRPLQDMM GMGGMMVRGP PPPYHSKPGD QWPPGMGAQL RGPMDVQDPM QLRGGPPFPG
   601  PRFPGNQIQR VPGFGGMQSM PMEVPMNAMQ RPVRPGMGWT EDLPPMGGPS NFAQNTMPYP
   661  GGQGEAERFM TPRVREELLR HQLLEKRSMG MQRPLGMAGS GMGQSMEMER MMQAHRQMDP
   721  AMFPGQMAGG EGLAGTPMGM EFGGGRGLLS PPMGQSGLRE VDPPMGPGNL NMNMNVNMNM
   781  NMNLNVQMTP QQQMLMSQKM RGPGDLMGPQ GLSPEEMARV RAQNSSGVMG GPQKMLMPSQ
   841  FPNQGQQGFS GGQGPYQAMS QDMGNTQDMF SPDQSSMPMS NVGTTRLSHM PLPPASNPPG
   901  TVHSAPNRGL GRRPSDLTIS INQMGSPGMG HLKSPTLSQV HSPLVTSPSA NLKSPQTPSQ
   961  MVPLPSANPP GPLKSPQVLG SSLSVRSPTG SPSRLKSPSM AVPSPGWVAS PKTAMPSPGV
  1021  SQNKQPPLNM NSSTTLSNME QGTLPPSGPR SSSSAPPANP PSGLMNPSLP FTSSPDPTPS
  1081  QNPLSLMMTQ MSKYAMPSST PLYHNAIKTI ATSDDELLPD RPLLPPPPPP QGSGPGISNS
  1141  QPSQMHLNSA AAQSPMGMNL PGQQPLSHEP PPAMLPSPTP LGSNIPLHPN AQGTGGPPQN
  1201  SMMMAPGGPD SLNAPCGPVP SSSQMMPFPP RLQQPHGAMA PTGGGGGGPG LQQHYPSGMA
  1261  LPPEDLPNQP PGPMPPQQHL MGKAMAGRMG DAYPPGVLPG VASVLNDPEL SEVIRPTPTG
  1321  IPEFDLSRII PSEKPSSTLQ YFPKSENQPP KAQPPNLHLM NLQNMMAEQT PSRPPNLPGQ
  1381  QGVQRGLNMS MCHPGQMSLL GRTGVPPQQG MVPHGLHQGV MSPPQGLMTQ QNFMLMKQRG
  1441  VGGEVYSQPP HMLSPQGSLM GPPPQQNLMV SHPLRQRSVS LDSQMGYLPA PGGMANLPF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BCL9L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.67
Highest tissue expression: 19 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 19 nTPM
salivary gland: 16 nTPM
adipose tissue: 16 nTPM
skin: 16 nTPM
placenta: 15 nTPM
bone marrow: 15 nTPM

Single-cell type

alveolar cells type 1: 180 nCPM
endometrial secretory cells: 103 nCPM
endometrial glandular cells: 87 nCPM
endometrial luminal cells: 77 nCPM
vascular smooth muscle cells: 64 nCPM
alveolar cells type 2: 64 nCPM

Immune cell

gdT-cell: 0.4 nTPM
naive CD8 T-cell: 0.3 nTPM
MAIT T-cell: 0.2 nTPM
memory CD8 T-cell: 0.2 nTPM
naive CD4 T-cell: 0.2 nTPM
memory CD4 T-cell: 0.1 nTPM

Brain region

cerebellum: 41 nTPM
cerebral cortex: 27 nTPM
amygdala: 24 nTPM
thalamus: 24 nTPM
midbrain: 23 nTPM
basal ganglia: 23 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about BCL9L.

Disease | ImmuneIEDB

Conditions an epitope on BCL9L was assayed in.

narcolepsy B cell
multiple sclerosis B cell
peripheral nervous system disease B cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.24
gnomAD pLI: 1
gnomAD missense Z: 1.1
DepMap mean gene effect: -0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BCL9L in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

CTNNB1

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BCL9L as an antibody target. Whether an autoantibody or antibody against BCL9L could matter depends on whether native BCL9L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BCL9L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BCL9L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...